What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD
Jul 14, 2025 · Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and …
New Ingrezza Data Demonstrates Functional and Quality of Life ...
May 16, 2025 · New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.
Emerging Tardive Syndrome Treatments | Practical Neurology
Sep 18, 2023 · Discover cutting-edge treatments for tardive syndrome. Learn about FDA-approved meds, personalized approaches, and future perspectives in one place.
Treatment Strategies for Tardive Dyskinesia - U.S. Pharmacist
May 14, 2025 · The Clinician’s Tardive Inventory (CTI): a new clinical tool for documenting and rating tardive dyskinesia. J Clin Psychiatry. 2024;85 (1):23m14886. 12. Farber RH, Stull DE, …
A new era in the diagnosis and treatment of tardive dyskinesia
Tardive dyskinesia (TD) is a heterogeneous, hyperkinetic movement disorder induced by dopamine-receptor blocking agents that presents a unique challenge in the treatment of …
Tardive dyskinesia: Prevention, treatment, and prognosis
Oct 6, 2025 · INTRODUCTION Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder associated with the use of dopamine receptor-blocking agents, including …
Latest Treatments for Tardive Dyskinesia - HealthCentral
Mar 24, 2025 · Jump To TD-Specific Meds New Antipsychotics Brain Stimulation Outlook It can be scary when you or a loved one has been diagnosed with tardive dyskinesia (TD), a disorder …
List of 21 Tardive Dyskinesia Medications Compared - Drugs.com
Mar 5, 2024 · Compare risks and benefits of common medications used for Tardive Dyskinesia. Find the most popular drugs, view ratings and user reviews.
Serina Therapeutics Advances Once-Weekly Injectable VMAT2 ...
Jul 29, 2025 · Quiver AI Summary Serina Therapeutics, Inc. announced the advancement of SER-270, a novel once-weekly injectable vesicular monoamine transporter 2 (VMAT2) …
Valbenazine Phase 3 Study Confirms Safety, Efficacy for ...
Jun 4, 2024 · Valbenazine can be a safe, tolerable, and highly effective long-term treatment option for people with tardive dyskinesia (TD), according to the results of a post hoc study led …